Anti-Human LSD1 (Intermediate Domain) - 0.1 mg

Primary Monoclonal Antibodies>Apoptosis & Cell Biology

Next Day Ambient

Histone modifications mediate changes in gene expression by altering chromatin structure or by serving as a platform to recruit other proteins. LSD1 is a recently discovered amine oxidase that catalyzes the lysine-specific demethylation of histone proteins via an FAD-dependent oxidative reaction (1). Methylation on histone H3-K9 is thought to play an important role in heterochromatin formation, while methylation on arginine and some lysine residues (such as H3-K4) is associated with active transcription (2). LSD1 associates with various proteins, including HDAC1/2, CoREST, and BHC80, that act to regulate LSD1 activity in vivo, and in a histone H3-K4-specific methylase complex that is involved in transcriptional regulation (3, 4). Experiments have shown that CoREST, a SANT domain-containing corepressor (5) acts to enhance LSD1 activity, while BHC80, a PHD domain-containing protein (6), inhibits CoREST/LSD1 activity in vitro (3). LSD1-mediated histone demethylation thus may have significant effects on gene expression.

This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.

Polyclonal Antibody, LSD1, Lysine-Specific Histone Demethylase, Amine Oxidase Flavin Containing Domain Protein 2, AOF2 , Human, Anti-Human LSD1 (Intermediate Domain), LSD1 Antibody, AOF2, KDM1, LSD1, BHC110, AOF2, KIAA0601, Lysine-specific histone demethylase 1A, BRAF35-HDAC complex protein BHC110